Patents by Inventor Detlef Schlondorff

Detlef Schlondorff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody and chemokine constructs and their use in the treatment of infections of immunological diseases
    Publication number: 20050191702
    Abstract: The invention is directed to chimeric polypeptides, e.g., bispecific antibodies, comprising a chemokine receptor binding domain and a T cell surface polypeptide or cell toxin binding domain, nucleic acids that encode them, and methods of making and using them. The chimeric polypeptides of the invention can include, be bound to, or attached to, a cell toxin. The invention is also directed to pharmaceutical compositions and methods for making and using them, including the treatment of immunological disorders, such as autoimmune diseases, and for the targeted elimination of cells, e.g., T lymphocytes and other cells latently infected with a primate immunodeficiency virus, such as a human immunodeficiency virus, e.g., HIV-1.
    Type: Application
    Filed: September 26, 2003
    Publication date: September 1, 2005
    Inventors: Matthias Mack, Detlef Schlondorff, Michael Spring
  • Bispecific antibody and chemokine receptor constructs
    Patent number: 6723538
    Abstract: The invention is directed to chimeric polypeptides, e.g., bispecific antibodies, comprising a chemokine receptor binding domain and a T cell surface polypeptide or cell toxin binding domain, nucleic acids that encode them, and methods of making and using them. The chimeric polypeptides of the invention can include, be bound to, or attached to, a cell toxin. The invention is also directed to pharmaceutical compositions and methods for making and using them, including the treatment of immunological disorders, such as autoimmune diseases, and for the targeted elimination of cells, e.g., T lymphocytes and other cells latently infected with a primate immunodeficiency virus, such as a human immunodeficiency virus, e.g., HIV-1.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: April 20, 2004
    Assignee: Micromet AG
    Inventors: Matthias Mack, Detlef Schlondorff, Michael Spring
  • Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
    Publication number: 20030017979
    Abstract: The invention is directed to chimeric polypeptides, e.g., bispecific antibodies, comprising a chemokine receptor binding domain and a T cell surface polypeptide or cell toxin binding domain, nucleic acids that encode them, and methods of making and using them. The chimeric polypeptides of the invention can include, be bound to, or attached to, a cell toxin. The invention is also directed to pharmaceutical compositions and methods for making and using them, including the treatment of immunological disorders, such as autoimmune diseases, and for the targeted elimination of cells, e.g., T lymphocytes and other cells latently infected with a primate immunodeficiency virus, such as a human immunodeficiency virus, e.g., HIV-1.
    Type: Application
    Filed: September 5, 2001
    Publication date: January 23, 2003
    Inventors: Matthias Mack, Detlef Schlondorff, Michael Spring